GeoVax Labs, Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022; filed November 9, 2022. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies. Its programs include Phase 2 COVID-19 vaccine trials and a Phase 1/2 trial of Gedeptin for advanced head and neck cancer.
Financial performance
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Grant and collaboration revenue | $0 | $30,414 | $81,526 | $220,539 |
| Research and development expense | $2.72 million | $1.22 million | $5.36 million | $2.66 million |
| General and administrative expense | $1.25 million | $757,432 | $3.36 million | $2.56 million |
| Net loss | $3.97 million | $1.95 million | $8.64 million | $4.83 million |
| Basic and diluted loss per share | $0.17 | $0.31 | $0.63 | $0.80 |
| Operating cash used | Not stated for quarter | Not stated for quarter | $11.97 million | $4.51 million |
GeoVax reported no product sales. Operating margins are not meaningful given negligible grant revenue and continued operating losses. Q3 operating expenses rose $1.99 million year over year, primarily reflecting increased clinical-trial, manufacturing, personnel and other development activity. Nine-month expenses rose $3.50 million. Lower grant revenue and the absence of the prior-year $172,056 PPP-loan forgiveness gain also contributed to the greater nine-month net loss.
Financial position and capital
- Cash and cash equivalents were $34.68 million at September 30, 2022, versus $11.42 million at December 31, 2021. Working capital was $31.35 million, up from $6.19 million.
- Total assets were $38.57 million; total liabilities were $6.79 million, including $4.79 million of current liabilities and $2.00 million of noncurrent accrued technology-license fees. The filing reports no interest expense in 2022 and no outstanding borrowing balance on the balance sheet.
- Nine-month financing cash inflow was $35.35 million, mainly from equity and warrant transactions. Operating cash use increased to $11.97 million; investing cash use was $134,258.
- Shares outstanding increased to 26.33 million from 6.38 million at year-end 2021. At September 30, 14.35 million potentially dilutive shares from options and warrants were excluded from diluted loss per share as antidilutive.
Changes, outlook and risks
- Revenue declined as grant funding and the timing of grant-related expenditures changed; all grant funds approved for direct use by GeoVax had been utilized by September 30.
- Management expected existing cash to fund operations for at least the next 12 months, but anticipated continuing operating losses and negative operating cash flows and said additional capital would be needed. Future R&D and G&A expenses were expected to rise as programs advance; no specific earnings or revenue guidance was provided.
- Management highlighted uncertainty in trial timing and costs, manufacturing needs, regulatory approvals and future financing. If adequate financing is unavailable, the company may delay, scale back or discontinue development programs.
- Commitments included approximately $1.2 million of non-cancellable contract-manufacturing obligations, $612,000 of other non-cancellable vendor commitments, and approximately $409,000 of unrecorded future minimum license payments. The office/laboratory lease was due to expire December 31, 2022, and the company expected to extend it.
- The filing reported no legal proceedings and no significant changes in internal control over financial reporting. Management concluded disclosure controls were effective.
Important facts for investors to verify
- Trial progress, results, timelines and cash requirements for GEO-CM04S1 and Gedeptin, as well as the status of earlier-stage programs.
- Cash burn and whether the stated minimum 12-month cash runway remains valid as development and manufacturing spending changes.
- Potential dilution from outstanding warrants and options, including 7.5 million May 2022 investment options and other warrants.
- Timing and terms of any additional financing, collaborations or grant support, given the company’s reliance on external capital.
- A filing inconsistency in the MD&A: its interest-income discussion lists 2022 amounts of $2,431 and $877 for the three- and nine-month periods, respectively, while the financial statements report $2,431 and $3,747. The nine-month figure should be confirmed.